Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 9/20 | 0.82 |
| ▸ | MRGPRX1 | Q96LB2 | 6/20 | 0.43 |
| ▸ | TSPO | P30536 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872123 | 1.00 | TLR4 (0.82) | TLR4MRGPRX1TSPOHRH1MAPK14 | |
| SCHEMBL872084 | 0.97 | TLR4 (0.82) | TLR4MRGPRX1TSPOHRH1MAPK14 | |
| SCHEMBL871895 | 0.94 | TLR4 (0.81) | TLR4MRGPRX1TSPOHRH1MAPK14 | |
| SCHEMBL871637 | 0.92 | TLR4 (0.70) | TLR4MRGPRX1TSPOHRH1MAPK14 | |
| SCHEMBL871496 | 0.92 | TLR4 (0.82) | TLR4MRGPRX1TSPOHRH1 | |
| SCHEMBL871281 | 0.92 | TLR4 (0.79) | TLR4MRGPRX1TSPOHRH1 | |
| SCHEMBL871428 | 0.92 | TLR4 (0.82) | TLR4MRGPRX1TSPOHRH1 | |
| SCHEMBL872544 | 0.90 | TLR4 (0.68) | TLR4MRGPRX1TSPOHRH1MAPK14 | |
| Resatorvid SCHEMBL1821271 | 0.90 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1 | |
| SCHEMBL872569 | 0.90 | TLR4 (0.79) | TLR4MRGPRX1TSPOHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1334966-B1 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE SULFONAMIDES AND INTERMEDIATES FOR THEIR SYNTHESIS | TAKEDA PHARMACEUTICAL (JP) | 2011-05-04 | — | — | EP | disclosed |
| US-6982344-B2 | Process for preparation of optically active sulfonamides and intermediates for their synthesis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040049041-A1 | Process for preparation of optically active sulfonamides and intermediates for their synthesis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1334966-A1 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE SULFONAMIDES AND INTERMEDIATES FOR THEIR SYNTHESIS | Takeda Chemical Industries, Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049041-A1 | Process for preparation of optically active sulfonamides and intermediates for their synthesis | STS, ARSA, SULT1A1 | TLR4 4118/4885MRGPRX1 2708/4885TSPO 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.